Nephrogenic Systemic Fibrosis Risk Associated with Gadolinium-Based Contrast Agents in Patients with Chronic Kidney Disease

Patient Risk Stratification

Patients with advanced kidney disease (eGFR <30 mL/min/1.73m²) are at significant risk of developing nephrogenic systemic fibrosis (NSF) when exposed to certain gadolinium-based contrast agents (GBCAs), particularly group I linear agents, while the risk is very low with newer group II agents even in severe kidney disease 1, 2, 3
Patients undergoing renal replacement therapy (dialysis) are at high risk of NSF 1, 3
Patients with acute kidney injury (AKI) are at high risk of NSF 1, 3
The risk of NSF is significantly increased with repeated doses or higher-than-recommended doses of group I GBCAs 3

GBCA Classification and Risk

Group I GBCAs (linear agents) are associated with the highest risk of NSF; nearly all unconfounded cases of NSF are linked to these agents 1, 2
Group II GBCAs (including gadobenate dimeglumine and macrocyclic agents) are associated with a very low risk of NSF 1, 2
Group III GBCAs (including gadoxetate disodium) are likely associated with a very low risk of NSF, but there is insufficient confirmatory evidence 1, 2

Clinical Recommendations

For patients with CKD stage 4-5 (eGFR <30 mL/min/1.73m²) and AKI, group II GBCAs should not be withheld or delayed if harm would result from not proceeding with an indicated contrast-enhanced MRI 1, 4
The lowest diagnostic dose of GBCA should be used 1, 5
Direct communication between radiologist and referring provider regarding NSF risk is suggested for group III GBCA administration 1
On-label dosing of group II or group III GBCAs does not have a clinically important risk of nephrotoxicity 1
The risk of withholding necessary diagnostic imaging may outweigh the very low risk of NSF with group II agents 4

Gadolinium-Based Contrast in Acute Kidney Injury

Introduction to Gadolinium-Based Contrast Agents

The American College of Radiology and the National Kidney Foundation recommend that group II gadolinium-based contrast media (macrocyclic agents) should not be withheld in patients with acute kidney injury (AKI) when clinically indicated, as the risk of nephrogenic systemic fibrosis is extremely low and the potential harm from delaying or withholding necessary diagnostic imaging likely outweighs this minimal risk 6, 7

Risk Stratification for Nephrogenic Systemic Fibrosis

Group II GBCAs (macrocyclic agents) carry an exceedingly low risk of NSF—much less than 1%—even in patients with AKI or severe renal impairment (eGFR <30 mL/min/1.73m²) 6, 7

Clinical Decision-Making

The 2021 American College of Radiology-National Kidney Foundation consensus states that withholding group II GBCM in AKI patients likely causes more harm than benefit in most clinical situations, representing a paradigm shift from older 2014 Kidney Disease: Improving Global Outcomes guidelines that recommended avoiding gadolinium in severe renal impairment (GFR <15 mL/min/1.73m²) 6, 7, 8, 9

Balancing Risk vs. Benefit

The risk of missing critical cardiac pathology often poses greater morbidity and mortality risk than the minimal NSF risk with group II agents, and delaying diagnosis can lead to inappropriate treatment decisions, progression of disease, and worse outcomes 6, 7

MRI with Gadolinium in CKD with eGFR 35

Introduction to Safe MRI Practices

The American College of Radiology and National Kidney Foundation recommend that it is safe to perform an MRI with gadolinium-based contrast agents (specifically Group II macrocyclic agents) in a patient with CKD and eGFR 35 mL/min/1.73 m², and the risk of withholding necessary diagnostic imaging likely outweighs the extremely low risk of nephrogenic systemic fibrosis (NSF) 10

Pre-Procedure Considerations

The American College of Radiology and National Kidney Foundation consensus statements suggest that kidney function screening is optional for Group II GBCAs in patients with eGFR >30 mL/min/1.73 m², and no special dialysis arrangements are needed for patients with eGFR 35 mL/min/1.73 m² 10

Risk-Benefit Analysis

The American College of Radiology and National Kidney Foundation guidelines imply that the harm of delaying or withholding a clinically indicated MRI in patients with CKD and eGFR 35 mL/min/1.73 m² may outweigh the extremely low risk of NSF, as the risk of NSF with Group II agents in this eGFR range is negligible 10

Nephrogenic Systemic Fibrosis Prevention Strategies

Primary Prevention Strategy: Agent Selection

The American College of Radiology recommends avoiding Group I linear gadolinium-based contrast agents and using Group II macrocyclic agents at the lowest diagnostic dose (0.1 mmol/kg) in all patients, particularly those with severe kidney disease, to reduce the risk of Nephrogenic Systemic Fibrosis (NSF) 11, 12
The use of Group II agents, such as gadobenate dimeglumine, gadoterate meglumine, gadobutrol, and gadoteridol, carries a very low NSF risk, with zero NSF cases reported in a systematic review of 4,931 administrations in patients with stage 4-5 CKD 13, 11
Group III GBCM (gadoxetate disodium) has no unconfounded NSF cases reported, but limited data in high-risk patients, and requires kidney function screening and provider communication when eGFR <30 mL/min/1.73m² 11, 13

Risk Stratification for NSF

Patients undergoing renal replacement therapy (dialysis), acute kidney injury (AKI), or stage 4-5 CKD (eGFR <30 mL/min/1.73m²) are at highest risk for NSF, especially with repeated or high off-label doses of Group I GBCM 11, 12
The risk of NSF is negligible with Group II agents in patients with stage 3 CKD (eGFR 30-59 mL/min/1.73m²) 11
Patients with eGFR ≥60 mL/min/1.73m² have no published NSF cases 11, 12

Dose Optimization

The American College of Radiology recommends using the lowest diagnostic dose (0.1 mmol/kg) of Group II and III GBCM to minimize the risk of NSF 11, 12
Repeated high doses of Group I agents increase the risk of NSF, with a 19% incidence reported in one study of 58 AKI patients receiving high-dose Group I GBCM 12
If subsequent doses of Group II/III GBCM are necessary, they should not be delayed if urgent, but delayed >24 hours if not urgent, to promote clearance 11, 12

Clinical Decision Algorithm

For patients with eGFR <30 mL/min/1.73m² or AKI, the benefit of diagnostic imaging with Group II GBCM outweighs the very low NSF risk, and kidney function screening is optional but necessary for Group III agents 11, 12
On-label dosing (0.1 mmol/kg) of Group II/III agents does not cause clinically important nephrotoxicity 11, 12

Mechanism of Risk Reduction

The difference in NSF risk among GBCM groups relates to kinetic lability, with linear agents (Group I) more readily releasing free gadolinium ions compared to macrocyclic agents (Group II), which are thermodynamically stable and kinetically inert 14, 13
The upper bound 95% CI for NSF risk with Group II agents in stage 5D CKD (dialysis patients) is 0.2% (1 case per 500 exposed), and for stage 5 CKD is 0.5% (1 case per 200 exposed), based on zero observed cases 13

Gadolinium Safety in Hemodialysis Patients

Introduction to GBCA Safety

The American College of Radiology categorizes GBCAs into three groups based on NSF risk, with Group II (macrocyclic agents and gadobenate dimeglumine) being the preferred choice due to their very low risk of NSF (15)
Group II GBCAs can be safely administered to hemodialysis patients without initiating or altering dialysis schedules, as the risk of nephrogenic systemic fibrosis is exceedingly low (<0.5%) (16, 15, 17)

GBCA Classification and Usage

The American College of Radiology recommends using only Group II GBCAs, which include macrocyclic agents such as gadoterate meglumine, gadobutrol, and gadoteridol, as well as the linear ionic agent gadobenate dimeglumine (15)
Zero NSF cases were reported in 4,931 administrations to stage 4-5 CKD patients, with an upper bound 95% CI for NSF risk in dialysis patients of 0.2% (1 in 500) (15)

Dialysis Management After GBCA Administration

The American College of Radiology recommends not initiating, accelerating, or altering dialysis schedules based on GBCA administration, as the risks associated with dialysis outweigh the very low NSF risk from Group II/III agents (16, 17, 18, 19)
Hemodialysis effectively removes GBCAs from the body, but the reduction in NSF risk is only theoretical and unproven in randomized trials (16, 17)

Clinical Decision Algorithm for Hemodialysis Patients

The American College of Radiology recommends using standard on-label doses (0.1 mmol/kg) of Group II GBCAs, and avoiding repeat injections when possible (17)
Patients should be informed of the potential NSF risk, although it is exceedingly low with Group II agents, and the reasons why GBCA-enhanced imaging is indicated (16, 18)

Important Safety Considerations

Nephrotoxicity is not a concern at on-label doses of Group II/III GBCAs, with no well-controlled studies demonstrating clinically important nephrotoxicity risk (16, 17, 18)
Hemodialysis is more effective than peritoneal dialysis for GBCA removal, but switching from peritoneal to hemodialysis to reduce NSF risk is unproven and not recommended (16, 17)
No prophylaxis reduces NSF risk, and risk mitigation strategies include using Group II GBCAs and awaiting kidney function recovery when feasible (16, 17, 18)

Safety and Use of Group II Gadolinium‑Based Contrast Agents in Chronic Kidney Disease

Overall Safety and Risk

The 2021 ACR‑NKF consensus states that Group II gadolinium‑based contrast agents (macrocyclic agents and gadobenate dimeglumine) can be administered safely to patients with chronic kidney disease at any estimated glomerular filtration rate (eGFR), including those with severe CKD (eGFR < 30 mL/min/1.73 m²) and dialysis patients, because the risk of nephrogenic systemic fibrosis (NSF) is extremely low and withholding necessary imaging is likely to cause greater harm. Evidence level: large observational cohort (4,931 administrations) showing zero NSF cases. 20
In that cohort of 4,931 Group II GBCA administrations to patients with stage 4–5 CKD, no NSF cases were reported. This provides a robust safety signal for this population. Evidence level: retrospective registry data. 20
The upper‑bound 95 % confidence interval for NSF risk after Group II GBCA exposure is 0.2 % (1 in 500) for dialysis patients and 0.5 % (1 in 200) for stage 5 CKD patients, indicating that even the worst‑case risk remains very low. Evidence level: statistical analysis of the same registry. 20

eGFR‑Based Clinical Decision‑Making

Patients with eGFR ≥ 30 mL/min/1.73 m² (CKD Stages 1‑3)

Group II GBCAs may be administered without restriction. Evidence level: consensus guideline based on extensive safety data. 20
Kidney‑function screening is optional before administration; routine testing is not required and may delay needed imaging. Evidence level: guideline recommendation. [20][21]

Patients with eGFR < 30 mL/min/1.73 m² (CKD Stages 4‑5)

Do not withhold or delay Group II GBCA use when the contrast‑enhanced MRI is clinically indicated; the potential harm from delayed or missed diagnosis outweighs the minimal NSF risk. Evidence level: expert consensus. 20
Use standard on‑label dosing (0.1 mmol/kg); reduced (half or quarter) dosing is not recommended. Evidence level: guideline dosing recommendation. [20][21]
No need to contact the referring provider before administration of a Group II agent, provided the indication is clear. Evidence level: practice recommendation. 21

Acute Kidney Injury (AKI)

When clinically indicated, proceed with Group II GBCA administration despite unreliable eGFR estimates in AKI; the benefit of accurate imaging supersedes the negligible NSF risk. Evidence level: consensus guidance. [20][21]

Dialysis Considerations

Do not initiate, accelerate, or modify established dialysis schedules solely because a Group II GBCA was administered. This departs from older practices that attempted dialysis‑based GBCA clearance. Evidence level: guideline recommendation. 20

Dosing and Repeat Administration

Use the lowest diagnostic dose (0.1 mmol/kg) for all patients, irrespective of on‑label or off‑label use. Evidence level: consensus dosing guideline. [20][21]
For patients with eGFR ≥ 30 mL/min/1.73 m², multiple closely spaced doses carry a very small NSF risk. Evidence level: expert opinion based on safety data. 20
For patients with eGFR < 30 mL/min/1.73 m², the risk of repeat dosing is not well‑evaluated; clinicians should weigh necessity carefully. Evidence level: acknowledged data gap. 20
If the repeat study is not urgent, allow > 24 hours between doses or schedule an intercurrent dialysis session to enhance GBCA clearance. Evidence level: practical recommendation. 20

Pediatric Population

The same safety and dosing recommendations for Group II GBCAs apply to infants and children without modification. Evidence level: guideline extension to pediatric patients. 20
Pediatric kidney function should be assessed with pediatric‑specific equations (e.g., Bedside Schwartz or CKiD) rather than adult eGFR formulas. Evidence level: expert recommendation. 20
Zero unconfounded NSF cases have been reported in children who received Group II agents. Evidence level: pediatric safety registry. 20
Only 23 NSF cases have been reported in children ≥ 6 years (1997‑2012), and the majority involved Group I linear agents, not Group II agents. Evidence level: historical surveillance data. 20
No NSF cases have been reported in neonates or infants, despite many having eGFR < 30 mL/min/1.73 m². Evidence level: observational data. 20

Nephrotoxicity Considerations

On‑label dosing of Group II (and Group III) GBCAs does not cause clinically important nephrotoxicity, so concerns about kidney injury should not influence the decision to use these agents at standard doses. Evidence level: consensus statement. 20

Group III Gadolinium Agents (Gadoxetate Disodium)

Although data are limited, Group III agents appear to have a very low NSF risk; however, kidney‑function screening is still recommended before their use. Evidence level: guideline precaution. 21
When eGFR < 30 mL/min/1.73 m², direct communication between the radiologist and the referring provider is suggested to discuss the risk‑benefit balance. Evidence level: practice recommendation. 21
Given the more robust safety data for Group II agents, preferential use of Group II agents is advised when either agent class could be employed. Evidence level: expert consensus.

All statements are derived from the 2021 ACR‑NKF consensus guideline and associated observational evidence.